is ozempic a glp-1 Drug Can Cause Rare, Potentially Blinding Side Effect, EMA Warns More people with type 1
Description
Gastroenterology 155 , 14631473 (2018)

Note that the costs, dosages, and approved uses are U.S.-based

Reference: Willard FS et al
In addition, there are new and innovative molecule types in the obesity pipeline, including monoclonal antibodies, antibody-drug conjugates, nanoparticle-drug conjugates, peptides, radiopharmaceuticals, recombinant proteins, and gene therapies, among others
